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AbstrAct
Introduction Chronic obstructive pulmonary disease 
(COPD) is a progressive inflammatory lung disease 
with cigarette smoke as the main risk factor for its 
development. Since not every smoker develops COPD, 
other factors likely underlie differences in susceptibility to 
develop COPD. Here, we tested if DNA methylation may be 
such a factor by assessing the association between DNA 
methylation levels and COPD in never and current smokers 
from the general population.
Methods For the current study, 1561 subjects were non-
randomly selected from the LifeLines cohort study. We 
included 903 never smokers and 658 current smokers with 
and without COPD, defined as pre-bronchodilator forced 
expiratory volume in 1 s/forced vital capacity (FEV1/FVC) 
<70%. Subsequently, we performed robust regression 
analysis on whole blood DNA methylation levels of 420 938 
CpG sites with COPD as outcome.
results None of the CpG sites in both the never and 
the current smokers were genome-wide significantly 
associated with COPD. CpG site cg14972228 annotated 
to SIPAL3 was most significant (p=5.66×10−6) in the 
never smokers, while CpG site cg08282037 annotated to 
EPS8L1 was most significant (p=1.45×10−5) in the current 
smokers.
conclusion In contrast to a previous, smaller study, we 
did not observe any significant association between DNA 
methylation levels and the presence of COPD, independent 
of smoking status. Apparently, DNA methylation studies are 
highly variable.
IntroductIon
Chronic obstructive pulmonary disease 
(COPD) is a progressive inflammatory lung 
disease, characterised by persistent airflow 
limitation. Patients with COPD suffer from 
severe respiratory symptoms, resulting in a 
worse quality of life. The development of 
COPD is associated with both genetic and 
environmental factors and their interactions. 
Although exposure to cigarette smoke is 
the main risk factor for the development of 
COPD, not every smoker will develop COPD.
The results of the genome-wide associa-
tion studies1 2 and genome-wide interaction 
studies3 that have been performed so far indi-
cate that only a small part (approximately 
5.5%) of the so called ‘susceptibility to 
develop COPD’ can be explained by genetic 
variation.4 As a consequence, the epigenome 
is increasingly recognised as an important 
link between the inherited genome and 
environmental exposures. One well-defined 
epigenetic modification is DNA methylation, 
which is tissue-specific and involves binding of 
a methyl group to a cytosine base adjacent to 
a guanine base, a so-called CpG site, leading 
to changes in gene expression.5 Therefore, 
differences in DNA methylation might partly 
explain the variance in the susceptibility 
to develop COPD. In the current study, we 
assessed whether differences in DNA meth-
ylation levels are associated with COPD in a 
non-randomly selected subset of the general 
population of never and current smokers.
Methods
study population
For the current study, 1561 subjects were 
non-randomly selected from the LifeLines 
general population-based cohort study.6 7 The 
LifeLines cohort study is approved by the 
medial ethical committee of the University 
Medical Centrum Groningen, The Nether-
lands (METc 2007/152) and all participants 
have signed informed consent. Subjects were 
non-randomly selected based on smoking 
history (never smoker or current smoker 
with >5 pack years), COPD (defined by 
Key messages
 ► We did not identify any genome-wide significant 
association between COPD and DNA methylation in 
never and current smokers in a large, non-random 
sample from the general population.
 ► The results of our study are in contrast to a previous, 
smaller study, indicating that studies on DNA meth-
ylation might be highly variable.
 ► The high variability in DNA methylation studies 
should be taken into account when interpreting 
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pre-bronchodilator forced expiratory volume in 1 s/
forced vital capacity (FEV1/FVC) <70%) and job-related 
exposures. Pre-bronchodilator spirometry was performed 
with a Welch Allyn Version 1.6.0.489, PC-based Spiroper-
fect with CA Workstation software according to the ATS/
ERS guidelines. Technical quality and results were evalu-
ated by well-trained assistants and abnormal results were 
re-evaluated by a lung physician.
Measurements
DNA methylation levels in whole blood were deter-
mined using the Illumina Infinium Human Methyla-
tion 450K Array. After quality control, DNA methylation 
data presented as beta values were available for 420 938 
CpG sites.8
epigenome-wide association study
To analyse the association between genome-wide 
DNA methylation and COPD, we performed robust 
logistic regression analysis with COPD as outcome and 
DNA methylation as predictor, stratified for smoking 
status (never vs current). We adjusted for the potential 
confounders age, gender, pack years, batch effects and 
white blood cell composition and applied false discovery 
rate (FDR) correction for multiple testing.
results
subject characteristics
A total of 903 never smokers and 658 current smokers 
were included in this study. An overview of the subject 
characteristics is shown in table 1.
epigenome-wide association study
In both never and current smokers, none of the CpG sites 
were genome-wide significantly associated with COPD (see 
Manhattan plot in figure 1). In never smokers, CpG site 
cg14972228 on chromosome 19, annotated to Signal-In-
duced Proliferation-Associated 1-Like Protein 3 (SIPA1L3) 
and involved in the GTP-ase activating cascade, was most 
significant (p=5.66×10−6). While SIPA1L3 has been asso-
ciated with epithelial cell morphogenesis, polarity and 
cytoskeletal organisation in eye abnormalities, a similar 
role for SIPA1L3 in lung-related tissues has not yet been 
described.9 In current smokers, CpG site cg08282037 on 
chromosome 19, annotated to Epidermal Growth Factor 
Receptor Pathway Substrate 8-Related Protein 1 (EPS8L1), was 
most significant (p=1.45×10−5). It has been postulated 
that EPS8L1 can link growth factor stimulation to actin 
reorganisation, thereby playing a role in the regulation of 
actin cytoskeletal remodelling.10 However, the function 
of EPS8L1 in the respiratory system is currently unknown.
dIscussIon
To our knowledge, this is the first genome-wide methylation 
study with the main focus on COPD in a general popula-
tion-based sample of never and current smokers.11 The only 
other study exploring the association between genome-wide 
DNA methylation and COPD so far12 focused on a much 
more severe COPD phenotype than the common COPD 





Number of subjects, N (%) 903 (57.8) 658 (42.2)
Male, N (%) 508 (56.3) 375 (57.0)
Age (years), median (min–
max)
46 (18–80) 46 (22–79)





316 (35.0) 279 (42.4)
Lung function, mean (SD) 
  FEV1 (L) 3.5 (0.9) 3.4 (0.9) 
  FEV1%predicted (%)* 100.5 (14.5) 94.4 (14.9) 
  FEV1/FVC (%) 84.5 (8.2) 71.7 (8.8) 
Moderate COPD, N (%) † 56 (6.2) 100 (15.2)
*Calculated with GLI-2012 if possible.
†COPD GOLD stage >2 (FEV1/FVC <70% and FEV1 between 
50% and 80% of predicted).
COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity. 
Figure 1 Manhattan plot for the association between 
COPD and DNA methylation in never smokers (left) 
and current smokers (right). Robust logistic regression 
analysis was performed, adjusted for age, gender, pack 
years, batch effects and white blood cell composition. 
Vertical line indicates genome wide significance 
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phenotype we have studied. Our results are in contrast with 
those from Qui et al, which described a strong association 
between DNA methylation and COPD. Several reasons can 
be put forward as a potential explanation why the outcome 
of these two, on first sight, comparable studies is so different.
First, Qiu et al used the Illumina 27K array to determine the 
DNA methylation levels, while we used the Illumina 450K 
array. Of the CpG sites on the 27K array, 23 787 CpG sites 
were also present among the 420 938 CpG sites that passed 
quality control in our analysis, but all failed to reach signif-
icance (after applying FDR correction for multiple testing 
for 23 787 CpG sites as used by Qui et al). Qui et al identified 
349 CpG sites that were significant for their three selected 
phenotypes COPD, FEV1 and FEV1/FVC and replicated at 
p<10−3 in their replication cohort. All these 349 CpG sites 
were available in our study too. Hence, different Illumina 
platforms cannot explain the differences in the results of 
both studies.
Second, we adjusted for age, gender, pack years, batch 
effects and white blood cell composition while Qui et al 
decided to avoid potential over adjustment for age and sex, 
arguing that these confounders are already included in the 
definition of COPD. Nevertheless, they show that in their 
covariate-adjusted model, the association between COPD 
and DNA methylation remains highly significant. However, 
the p-values are considerably larger than in the unadjusted 
models and none of the CpG sites were significantly repli-
cated in their replication cohort. Interestingly, an unadjusted 
analysis in our cohort revealed several genome-wide signifi-
cant CpG sites (data not shown), but did not replicate any of 
their top hits. Since Qiu et al did not adjust for white blood 
cell composition, we could not determine if differences 
in white blood composition might explain the differences 
between both studies. Overall, adjustments for confounders 
definitively affect the results of the studies, but it is not clear 
if the adjustments can be held completely responsible for 
the observed differences between the studies.
Third, our cohort is a selected sample from the general 
population including subjects with mild to moderate 
severe COPD and controls. In contrast, Qiu et al included 
only patients with severe COPD based on a strict cut-off of 
FEV1% predicted of 70% together with a FEV1/FVC <70%. 
Furthermore, in our cohort only never smokers and current 
smokers are included, while ex-smokers are not present. 
These differences in smoking habits and phenotype between 
both cohorts might explain the differences between the 
results of both analyses to some extent.
Finally, both studies have a cross-sectional design and we 
cannot rule out the fact that COPD may also cause differ-
ential DNA methylation itself. Together with the different 
phenotypes of COPD in both studies, this might contribute 
to the observed differences between the studies. With respect 
to our study, some additional cohort specific characteristics 
have to be emphasised. Our DNA methylation cohort is a 
non-random selection of the LifeLines Cohort Study. Since 
COPD was one of the selection criteria, the percentages 
of COPD cases should not be interpreted as prevalence. 
Furthermore, COPD was defined as a fixed pre-bronchodi-
lator FEV1/FVC ratio below 70%. While this definition of 
COPD is commonly used, it is known that this definition can 
overestimate the number of COPD cases, especially in older 
subjects.13
In conclusion, we did not observe any genome-wide signif-
icant association between DNA methylation levels and the 
presence of COPD, independent of smoking status. Results 
of DNA methylation studies appear to be highly variable, 
which should be taken into account for the interpretation 
of future studies.
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